Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biotechnology Equipment

PUBLISHER: Grand View Research | PRODUCT CODE: 2067584

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2067584

Oligonucleotide Therapeutics Market Size, Share & Trends Analysis Report By Oligonucleotide Class (Antisense Oligonucleotides, Small Interfering RNA ), By Therapeutic Area, By Route of Administration, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Oligonucleotide Therapeutics Market Summary

The global oligonucleotide therapeutics market size was estimated at USD 7,200.00 million in 2025 and is projected to reach USD 29,608.38 million by 2033, growing at a CAGR of 19.40% from 2026 to 2033. The industry is witnessing rapid transformation as pharmaceutical and biotechnology companies increasingly focus on RNA-based medicines for the treatment of rare genetic disorders, oncology indications, neurological diseases, and chronic conditions.

Growing advancements in antisense oligonucleotides, siRNA therapeutics, and other RNA-targeting technologies are significantly expanding the therapeutic potential of gene-modulating medicines across a broad range of disease areas. The market is also benefiting from continuous innovation in delivery technologies such as lipid nanoparticles and GalNAc conjugates, which are improving drug stability, tissue-specific targeting, cellular uptake, and overall therapeutic efficiency. In addition, increasing regulatory approvals, expanding clinical pipelines, and rising commercialization of RNA-based therapies are strengthening industry confidence and encouraging broader investment in nucleic acid therapeutics development and next-generation precision medicine approaches worldwide.

Another major characteristic of the market is the increasing integration of advanced technologies such as artificial intelligence, automation, and computational biology into oligonucleotide drug discovery and development processes. Pharmaceutical companies and biotechnology firms are actively investing in digital drug discovery platforms to improve target identification, optimize oligonucleotide design, and accelerate preclinical development timelines. Strategic collaborations between RNA-focused biotechnology companies and technology-driven drug discovery firms are becoming increasingly common as the market shifts toward more efficient and data-driven therapeutic development models. At the same time, rising competition within the precision medicine landscape is encouraging companies to strengthen their RNA therapeutic pipelines through innovation-focused partnerships and platform expansion strategies.

Global Oligonucleotide Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oligonucleotide therapeutics market report based on oligonucleotide class, therapeutic area, route of administration, and region:

  • Oligonucleotide Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Antisense Oligonucleotides (ASOs)
  • Small Interfering RNA (siRNA)
  • Aptamers
  • microRNA (miRNA)
  • CpG Oligonucleotides
  • Other
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Neurology
  • Oncology
  • Cardiometabolic Disorders
  • Infectious Diseases
  • Ophthalmology
  • Other
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Subcutaneous
  • Intravenous
  • Intrathecal
  • Intramuscular
  • Other
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68040-924-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Oligonucleotide Class
    • 1.2.2. Therapeutic Area
    • 1.2.3. Route of Administration
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Oligonucleotide Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Oligonucleotide Therapeutics Market: Oligonucleotide Class Business Analysis

  • 4.1. Oligonucleotide Class Market Share, 2025 & 2033
  • 4.2. Oligonucleotide Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Oligonucleotide Class, 2021 to 2033 (USD Million)
  • 4.4. Antisense Oligonucleotides (ASOs)
    • 4.4.1. Antisense Oligonucleotides (ASOs) Market, 2021 - 2033 (USD Million)
  • 4.5. Small Interfering RNA (siRNA)
    • 4.5.1. Small Interfering RNA (siRNA) Market, 2021 - 2033 (USD Million)
  • 4.6. Aptamers
    • 4.6.1. Aptamers Market, 2021 - 2033 (USD Million)
  • 4.7. microRNA (miRNA)
    • 4.7.1. microRNA (miRNA)Market, 2021 - 2033 (USD Million)
  • 4.8. CpG Oligonucleotides
    • 4.8.1. CpG Oligonucleotides Market, 2021 - 2033 (USD Million)
  • 4.9. Other
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Oligonucleotide Therapeutics Market: Therapeutic Area Business Analysis

  • 5.1. Therapeutic Area Market Share, 2025 & 2033
  • 5.2. Therapeutic Area Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
  • 5.4. Neurology
    • 5.4.1. Neurology Market, 2021 - 2033 (USD Million)
  • 5.5. Oncology
    • 5.5.1. Oncology Market, 2021 - 2033 (USD Million)
  • 5.6. Cardiometabolic Disorders
    • 5.6.1. Cardiometabolic Disorders Market, 2021 - 2033 (USD Million)
  • 5.7. Infectious Diseases
    • 5.7.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 5.8. Ophthalmology
    • 5.8.1. Ophthalmology Market, 2021 - 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Oligonucleotide Therapeutics Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Subcutaneous
    • 6.4.1. Subcutaneous Market, 2021 - 2033 (USD Million)
  • 6.5. Intravenous
    • 6.5.1. Intravenous Market, 2021 - 2033 (USD Million)
  • 6.6. Intrathecal
    • 6.6.1. Intrathecal Market, 2021 - 2033 (USD Million)
  • 6.7. Intramuscular
    • 6.7.1. Intramuscular Market, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Oligonucleotide Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Oligonucleotide Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Ionis Pharmaceuticals
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Alnylam Pharmaceuticals
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sarepta Therapeutics
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Biogen
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Novartis
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Roche
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Arrowhead Pharmaceuticals
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Wave Life Sciences
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Silence Therapeutics
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Nitto Denko Avecia
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68040-924-3

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global oligonucleotide therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 5 Global oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 6 Global oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 7 North America oligonucleotide therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 9 North America oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 10 North America oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 11 U.S. oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 12 U.S. oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 13 U.S. oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 14 Canada oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 15 Canada oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 16 Canada oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 17 Mexico oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 18 Mexico oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 19 Mexico oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 20 Europe oligonucleotide therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 22 Europe oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 23 Europe oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 24 UK oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 25 UK oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 26 UK oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 27 Germany oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 28 Germany oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 29 Germany oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 30 France oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 31 France oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 32 France oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 33 Italy oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 34 Italy oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 35 Italy oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 36 Spain oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 37 Spain oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 38 Spain oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 39 Norway oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 40 Norway oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 41 Norway oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 42 Denmark oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 43 Denmark oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 44 Denmark oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 45 Sweden oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 46 Sweden oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 47 Sweden oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific oligonucleotide therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 52 Japan oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 53 Japan oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 54 Japan oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 55 China oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 56 China oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 57 China oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 58 India oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 59 India oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 60 India oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 61 Australia oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 62 Australia oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 63 Australia oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 64 South Korea oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 65 South Korea oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 66 South Korea oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 67 Thailand oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 68 Thailand oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 69 Thailand oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 70 Latin America oligonucleotide therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 72 Latin America oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 73 Latin America oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 74 Brazil oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 75 Brazil oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 76 Brazil oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 77 Argentina oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 78 Argentina oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 79 Argentina oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa oligonucleotide therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 84 South Africa oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 85 South Africa oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 86 South Africa oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 90 UAE oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 91 UAE oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 92 UAE oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 93 Kuwait oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 94 Kuwait oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 95 Kuwait oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Oligonucleotide therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Oligonucleotide therapeutics market dynamics
  • Fig. 11 Oligonucleotide therapeutics market: Porter's five forces analysis
  • Fig. 12 Oligonucleotide therapeutics market: PESTLE analysis
  • Fig. 13 Oligonucleotide class market, 2021 - 2033 (USD Million)
  • Fig. 14 Antisense oligonucleotides (ASOs) market, 2021 - 2033 (USD Million)
  • Fig. 15 Small interfering RNA (siRNA) market, 2021 - 2033 (USD Million)
  • Fig. 16 Aptamers market, 2021 - 2033 (USD Million)
  • Fig. 17 microRNA (miRNA) market, 2021 - 2033 (USD Million)
  • Fig. 18 CpG oligonucleotides market, 2021 - 2033 (USD Million)
  • Fig. 19 Other market, 2021 - 2033 (USD Million)
  • Fig. 20 Therapeutic area market, 2021 - 2033 (USD Million)
  • Fig. 21 Neurology market, 2021 - 2033 (USD Million)
  • Fig. 22 Oncology market, 2021 - 2033 (USD Million)
  • Fig. 23 Cardiometabolic disorders market, 2021 - 2033 (USD Million)
  • Fig. 24 Infectious diseases market, 2021 - 2033 (USD Million)
  • Fig. 25 Ophthalmology market, 2021 - 2033 (USD Million)
  • Fig. 26 Other market, 2021 - 2033 (USD Million)
  • Fig. 27 Route of administration market, 2021 - 2033 (USD Million)
  • Fig. 28 Subcutaneous market, 2021 - 2033 (USD Million)
  • Fig. 29 Intravenous market, 2021 - 2033 (USD Million)
  • Fig. 30 Intrathecal market, 2021 - 2033 (USD Million)
  • Fig. 31 Intramuscular market, 2021 - 2033 (USD Million)
  • Fig. 32 Other market, 2021 - 2033 (USD Million)
  • Fig. 33 Oligonucleotide therapeutics market revenue, by region
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 42 Europe Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 France country dynamics
  • Fig. 48 France Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 53 Norway country dynamics
  • Fig. 54 Norway Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 55 Sweden country dynamics
  • Fig. 56 Sweden Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 57 Denmark country dynamics
  • Fig. 58 Denmark Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 59 Asia Pacific Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 Japan country dynamics
  • Fig. 61 Japan Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 China country dynamics
  • Fig. 63 China Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 64 India country dynamics
  • Fig. 65 India Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 66 Australia country dynamics
  • Fig. 67 Australia Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 68 South Korea country dynamics
  • Fig. 69 South Korea Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 Thailand country dynamics
  • Fig. 71 Thailand Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 Latin America Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 73 Brazil country dynamics
  • Fig. 74 Brazil Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 75 Argentina country dynamics
  • Fig. 76 Argentina Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 77 MEA Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 South Africa country dynamics
  • Fig. 79 South Africa Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 80 Saudi Arabia country dynamics
  • Fig. 81 Saudi Arabia Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 82 UAE country dynamics
  • Fig. 83 UAE Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 84 Kuwait country dynamics
  • Fig. 85 Kuwait Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 86 Company categorization
  • Fig. 87 Company market position analysis
  • Fig. 88 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!